Thomas A. Satterfield, Jr. filed Amendment No. 3 to a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 5,434,150 shares of OS Therapies Incorporated common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Thomas A. Satterfield, Jr. reported 5,434,150 shares of OS Therapies Incorporated common stock beneficially owned, representing 9.9% of the class (rounded down from 9.95% due to EDGAR field limitations).
  • Sole and shared power: Satterfield holds sole voting and dispositive power over 1,436,583 shares, and shared voting and dispositive power over 3,997,567 shares.
  • Convertible preferred stock: The reporting person holds 156,250 shares of Series A Senior Convertible Preferred Stock, currently convertible into an aggregate of 558,034 shares of common stock.
  • Warrants: Satterfield holds 1,775,747 warrants to purchase one share of common stock each, at an initial exercise price of $1.40 per share, subject to adjustment.
  • Blocker provisions: Both the Series A Preferred Stock and the warrants are subject to blocker provisions capping beneficial ownership at 9.95% of outstanding common stock upon conversion or exercise.
  • Shares outstanding basis: The percentage is calculated on 52,322,483 shares of common stock outstanding, combining 46,805,230 shares reported as of September 10, 2026, and an additional 5,517,253 shares reported in an October 19, 2026 filing.

Satterfield's Ownership Structure in OS Therapies as of September 30, 2026

According to the filing, Thomas A. Satterfield, Jr., a U.S. individual investor, holds his interest in OS Therapies Incorporated through a combination of direct common stock, convertible preferred stock, warrants, and positions through two affiliated entities. OS Therapies Incorporated, headquartered at 115 Pullman Crossing Road, Suite 103, Grasonville, MD 21638, has common stock identified by CUSIP number 68764Y207. The filing does not specify a ticker or exchange on the cover page of the Schedule 13G itself.

The filing discloses that two entities connected to Satterfield hold portions of the reported stake. Tomsat Investment and Trading Co., Inc., a corporation wholly owned by Satterfield and of which he serves as President, holds 767,859 shares of common stock, 178,571 shares issuable upon conversion of Series A Preferred Stock, and 375,001 shares issuable upon exercise of warrants. A.G. Family L.P., a partnership managed by a general partner controlled by Satterfield, holds 1,525,113 shares of common stock, 290,178 shares issuable upon conversion of Series A Preferred Stock, and 902,531 shares issuable upon exercise of warrants.

The filing states that if no blocker provisions applied, Satterfield could be deemed the beneficial owner of an aggregate of 5,475,836 shares of common stock, representing 10.02% of the issuer's outstanding common stock. As currently reported, the 5,434,150 shares consist of 3,142,055 shares of common stock held directly and 2,292,095 shares issuable upon conversion of preferred stock and exercise of warrants, representing the maximum permissible beneficial ownership under the applicable blocker provisions. Satterfield certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

What Was Disclosed

This Amendment No. 3 to Schedule 13G reports that Thomas A. Satterfield, Jr. beneficially owns 5,434,150 shares of OS Therapies Incorporated common stock, equal to 9.9% of the class, as of a triggering event dated September 30, 2026, with holdings spread across direct shares, convertible preferred stock, and warrants.